164 related articles for article (PubMed ID: 26518357)
1. The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.
Kodawara T; Higashi T; Negoro Y; Kamitani Y; Igarashi T; Watanabe K; Tsukamoto H; Yano R; Masada M; Iwasaki H; Nakamura T
Basic Clin Pharmacol Toxicol; 2016 May; 118(5):333-7. PubMed ID: 26518357
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide.
Kodawara T; Masuda S; Yano Y; Matsubara K; Nakamura T; Masada M
Biopharm Drug Dispos; 2014 Jul; 35(5):275-83. PubMed ID: 24615849
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
4. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
5. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
Narita M; Nagai E; Hagiwara H; Aburada M; Yokoi T; Kamataki T
Xenobiotica; 1993 Jan; 23(1):5-10. PubMed ID: 8484262
[TBL] [Abstract][Full Text] [Related]
7. Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.
Zhong ZY; Sun BB; Shu N; Xie QS; Tang XG; Ling ZL; Wang F; Zhao KJ; Xu P; Zhang M; Li Y; Chen Y; Liu L; Xia LZ; Liu XD
Acta Pharmacol Sin; 2016 Jul; 37(7):1002-12. PubMed ID: 27180979
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
9. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
10. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
[TBL] [Abstract][Full Text] [Related]
11. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan.
Rivory LP; Robert J
Cancer Chemother Pharmacol; 1995; 36(2):176-9. PubMed ID: 7767955
[TBL] [Abstract][Full Text] [Related]
12. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
[TBL] [Abstract][Full Text] [Related]
13. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
14. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
15. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
17. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
[TBL] [Abstract][Full Text] [Related]
19. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
[TBL] [Abstract][Full Text] [Related]
20. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
